CLL B cells with a bimodal CD38 expression pattern: Persistence of bimodal populations despite effective therapy for B-CLL [10]

Leukemia

Volumn 18, Issue 1, 2004, Pages 180-182

  Pittner, B T ^a   Jelinek, D F ^a   Kay, N E ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CYCLOPHOSPHAMIDE; PENTOSTATIN; RITUXIMAB;

ANTIGEN EXPRESSION; APOPTOSIS; B CELL LEUKEMIA; BLOOD CELL COUNT; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; LETTER; LEUKEMIA CELL; LYMPHOCYTE SUBPOPULATION; MONONUCLEAR CELL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL;

EID: 0742289552     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403151     Document Type: Letter

References (8)

1. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
2. Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK. Immunoglobulin V genes and CD38 expression in CLL. Blood 2000; 95: 2455-2457.
3. Jelinek DF, Tschumper RC, Geyer SM, Bone ND, Dewald GW, Hanson CA et al. Analysis of clonol B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001; 115: 854-861.
4. Matrai Z, Lin K, Dennis M, Sherrington P, Zuzel M, Pettitt AR et al. CD38 expression and IgVH gene mutation in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 1902-1903.
5. D'Arena G, Musto P, Cascavilla N, Del l'Olio M, Di Renzo N, Perla G et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001; 42: 109-114.
6. Hsi ED, Kopecky KJ, Appelbaum FR, Boldt D, Frey T, Loftus M et al. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2003; 120: 1017-1025.
7. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101: 1262-1269.
8. Zupo S, Isnardi L, Megna M, Massara R, Malavasi F, Dono M et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM anti-bodies and propensity to apoptosis. Blood 1996; 88: 1365-1374.